About
Small-cell lung cancer (SCLC), characterized by its aggressive nature has a poor overall 5-year survival rate (5-10%). The immune evasion program in SCLC is mediated by the low expression levels of molecules needed for T-cell receptor (TCR) recognition, major histocompatibility complex (MHC) class I. Chimeric Antigen Receptor T (CAR T) cells offer a promising strategy for SCLC, with the ability to target cancer cells in a TCR-independent manner. However, access to clinical-grade viral vectors to manufacture CAR T cells remains challenging.

In this webinar, Vimal Keerthi, will discuss his work on identifying CD276 (B7-H3) overexpression in primary human SCLC and developing a non-viral CRISPR- Cas9 knock-in (CKI) based platform against B7-H3 to manufacture CAR T cells for the treatment of SCLC. He will demonstrate the feasibility of this non-viral CAR T manufacturing platform, and how this provides a blueprint for immediate clinical translation overcoming the bottleneck of viral vector production.

Key learning objectives will include:
  • Learn more about homology directed repair (HDR) based CRISPR knock-in strategies to engineer T cells.

  • Explore how CRISPR/Cas9-engineered CAR T cells can target low-antigen SCLC.

  • Learn about the method and feasibility of scaling up clinical-grade production of non-viral CAR T cells for immediate clinical translation.
Presenter
1711576342-545c705c4e456278
Vimal Keerthi
Process Development and Manufacturing Scientist, Stanford University Center for Cancer Cell Therapy
Vimal Keerthi is a Process Development and Manufacturing Scientist in Dr. Steven Feldman’s group, at Stanford University Center for Cancer Cell Therapy (CCT). His work focuses on developing CAR T manufacturing platforms, helping bridge the gap from bench to bedside, and enabling clinical trials for cancer treatments.
Reserve Your Spot
First Name*
Last Name*
Email Address*
Organization / Company*
Job Title*
Country / Region*
At which stage of research are you currently?*
Fundamental research
Early preclinical
Late preclinical/process development
Clinical (Phase I–III)
Commercialization
I don't know
Not applicable
What part of your T cell workflow do you find the most challenging? *
Cell sourcing
Cell isolation
Cell expansion
Cell activation
Cell engineering
Other
I do not work with T cells
Please post any questions you might have for the speakers in the field below:
utm_bmcr_source
Registration Terms
This event is hosted by the Scientist.com family of companies. Specific brands and sites associated with this event include InsideScientific. By registering and participating, you acknowledge that your personal data will be processed by the webinar platform (BigMarker) and Scientist.com. You also agree to receive email communication from InsideScientific about this webinar and other programs of similar nature. The sponsor of this webinar is STEMCELL Technologies; by registering and participating, you acknowledge that your data will be processed in accordance with STEMCELL Technologies' Privacy Policy. You will receive email communication from STEMCELL Technologies about this webinar and programs of similar interest. You can withdraw your consent at any time from these communications.
Scientist.com Privacy Policy
✓ Yes, I consent to the registration terms.*
STEMCELL Technologies Privacy Policy
✓ Yes, I consent to the registration terms.*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.
Powered by BigMarker